Why 93% Of Aerovate Therapeutics' Value Just Went Up In Smoke

Aerovate Therapeutics (AVTE) said Monday its experimental blood pressure medicine failed in Phase 2 testing, and the biotech stock — which had been on an eight-day sprint — plummeted 93%.